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Abstract
Introduction The nutritional status of patients in the intensive
care unit (ICU) appears to decline not only during their stay in
the ICU but also after discharge from the ICU. Recent evidence
suggests that gut released peptides, such as ghrelin and
peptide YY (PYY) regulate the initiation and termination of meals
and could play a role in the altered eating behaviour of sick
patients. The aim of this study was to assess the patterns of
ghrelin and PYY levels during the stay of ICU patients in
hospital.
Methods Sixteen ICU patients (60 ± 4.7 years, body mass index
(BMI) 28.1 ± 1.7 kg/m2 (mean ± standard error of the mean))
underwent fasting blood sample collections on days 1, 3, 5, 14,
21 and 28 of their stay at Hammersmith and Charing Cross
Hospitals. Changes in appetite and biochemical and
anthropometric markers of nutritional status were recorded. A
comparison was made to a group of 36 healthy volunteers
matched for age and BMI (54.3 ± 2.9 years, p = 0.3; BMI 25.8
± 0.8 kg/m2 p = 0.2).
Results Compared to healthy subjects, ICU patients exhibited a
significantly lower level of ghrelin (day one 297.8 ± 76.3 versus
827.2 ± 78.7 pmol/l, p < 0.001) during their stay in the ICU.
This tended to rise to the normal level during the last three
weeks of hospital stay. Conversely, ICU patients showed a
significantly higher level of PYY (day one 31.5 ± 9.6 versus 11.3
± 1.0 pmol/l, p < 0.05) throughout their stay in the ICU and on
the ward, with a downward trend to the normal level during the
last three weeks of stay.
Conclusions Results from our study show high levels of PYY
and low levels of ghrelin in ICU patients compared to healthy
controls. There appears to be a relationship between the level of
these gut hormones and nutritional intake.
Introduction
Impaired appetite is a common feature of illness. A recent
review suggested that 10% to 40% of adult patients admitted
to hospital exhibit some level of nutritional depletion [1], with
much weight loss, occurring over the period of hospitalisation
[2]. This is a matter of particular concern for certain categories
of patients. Patients in intensive care units (ICUs) are a vulner-
able group. One report suggested 55 out of 129 patients
admitted to ICUs were already suffering from malnutrition [3].
Their nutritional status further declines during the intensive
APACHE = Acute physiology and Chronic Health Evaluation; BMI = body mass index; CRP = C-reactive protein; ICU = intensive therapy unit/inten-
sive care unit; MAC = muscle arm circumference; PYY/PYY3–36 = peptide YY or peptide tyrosine tyrosine; SEM = standard error of mean; VAS = 
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care and also after their ICU stay [3]. This study noted that
despite 20 years of intense awareness, malnutrition was still
highly prevalent in hospitalised patients and this continues to
affect patients' outcomes. At present, nutritional supplements
are used in most hospitals, but their effectiveness varies [4],
probably due to the influence of poor appetite. The mechanism
of poor nutritional intake in ICU patients remains unclear, but
gastric myoneural inhibition and gastrointestinal hypomotility
with delayed gastric emptying may be contributing factors.
Peptide hormones released from the gut, such as ghrelin and
peptide YY (PYY), which stimulate and inhibit the appetite,
respectively [5,6], might play a role in the altered eating behav-
iour of sick patients because the anorexia in sick hospitalised
patients is often characterised by a premature feeling of full-
ness and loss of hunger. Ghrelin, a 28 amino acid peptide, is
produced by the stomach and its level is highest in the fasting
state, rising sharply before, and falling within one hour of, a
meal [7]. Wren and colleagues [8] demonstrated that intrave-
nous ghrelin infusion stimulates appetite and food intake
potently in human and recent research showed that circulating
ghrelin levels decreased in normal weight subjects after a meal
[9]. Ghrelin, a newly discovered gut peptide is potentially an
important new peripheral signal to the brain to stimulate food
intake in human [8].
The levels of ghrelin and PYY in sick hospitalised patients are
unknown. Peptide YY is a naturally occurring peptide that is
released into the circulation by intestinal L-cells following food
ingestion. PYY3–36 is the major form of metabolically active
PYY in both the gut mucosal endocrine cells and the circula-
tion. In human volunteers, exogenous infusion of PYY 3–36
reduces food intake by 30% compared to placebo [10].
Recent work on patients with cardiac cachexia caused by
severe pulmonary hypertension showed an exaggerated and
early PYY response to a test meal when compared to control
subjects [11]. Research so far has demonstrated that PYY
physiologically inhibits appetite in human and suggests it is
likely to be important in the everyday regulation of food intake.
The aim of this study was to investigate the concentration of
ghrelin and PYY in patients during their stay in the ICU and,
secondarily, the relationship between these levels and meas-
ures of appetite and food intake.
Materials and methods
Study subjects
This was a prospective study undertaken at Hammersmith and
Charing Cross Hospitals, London. Local ethics committee
approval was obtained for the enrolment of both patients and
control subjects. Conscious patients with adequate mental
capacity gave written informed consent prior to enrolment; for
others, a close relative/partner gave written assent, with
deferred patient consent being obtained during recovery.
Patient refusal at this point resulted in complete withdrawal
from the study.
The inclusion criteria were: male and female patients between
the ages of 18 and 85 years who were anticipated to stay in
the ICU for longer than three days in the opinion of the consult-
ant. Exclusion criteria were: patients who were anticipated to
die, or stay less than three days in the ICU; those who were
known to be HIV or hepatitis B surface antigen positive; and
patients who were already enrolled in a therapeutic study. The
study was performed in accordance with the Declaration of
Helsinki.
ICU patients
Nutritional and medical data were collected from patients,
charts, medical notes, dieticians and medical teams. Patients
were followed clinically until discharge from hospital or death.
Visual analogue scale
As patients recovered from critical illness in intensive care they
were asked to complete a visual analogue scale (VAS) for
appetite [12]. This was repeated on the days that blood sam-
ples were collected throughout their stay. VAS questionnaires
were not obtained during intensive care stay as patients were
mainly fed nasogastrically or received parenteral nutrition, and
were not alert enough to reply to questions. Some patients
were never well enough to complete the VAS assessment.
Food intake
Food intake was estimated from food record charts completed
at ward level. Nurses were given instruction on how to com-
plete the intake charts. The nutritional content of the patients'
food record charts and healthy subjects' three-day diet diary
were calculated using computerised food tables in Dietplan5
(Forrest Hill Software Ltd, Sussex, UK).
Anthropometric measurements
Anthropometric indices, including triceps skinfold thickness,
muscle arm circumference (MAC) and weight were assessed
at the nearest point to ICU discharge [13,14]. The admission
weight was recorded from the notes if it was known, otherwise
it was recorded at the nearest point to ICU discharge. The
demi-span was measured to calculate the height in order to
compute body mass index (BMI) [15].
Blood sampling
Fasting blood samples were taken on days 1, 3, 5, 14, 21 and
28 of stay or date of discharge home. In the ICU, fasting blood
samples were taken at 6 a.m. In the ward, fasting blood sam-
ples were taken between 7 and 8 a.m. before starting break-
fast. Blood samples were centrifuged at 4°C; plasma was then
separated, frozen immediately and stored at -20°C until analy-
sis. Patients were followed after transfer to other wards, until
day 28 or discharge home if earlier.Available online http://ccforum.com/content/10/1/R10
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Results from albumin, total protein, C-reactive protein (CRP),
and haemoglobin concentrations were extracted from the
patient records.
Acute Physiology and Chronic Health Evaluation II
Acute Physiology and Chronic Health Evaluation (APACHE) II
and risk of death scores were calculated to stratify illness
severity on admission [16] and to anticipate prognosis.
Control volunteers
Healthy control volunteers were recruited by advertisement at
Hammersmith Hospital.
The inclusion criteria were; volunteers between the ages of 18
and 85 years. Exclusion criteria were: those subjects with a
history of significant chronic diseases or muscle wasting dis-
eases; smoking; substance abuse; pregnancy; medical or psy-
chiatric illness; and those who were known to be HIV or
hepatitis B surface antigen positive. An appetite questionnaire
(visual analogue scale) was completed for control subjects;
this was repeated on the days that blood samples were taken
and weight was recorded. Control subjects also completed a
three-day diet diary to determine their food intake. A tape and
callipers were used on their arm to measure MAC and triceps
skinfold thickness. Their height and weight were measured in
order to calculate their BMI. Subjects were asked to fast from
10 p.m. on the night before each visit and to have only water
to drink from midnight. One 10 ml fasting blood sample
between 7.30 and 9.30 a.m. on days 1, 3 and 5 were taken
from each volunteer.
Gut peptides assays
Plasma PYY and ghrelin were measured using 'established in-
house radioimmunoassays' as described previously [17,18].
Column chromatography
To confirm ghrelin and PYY like immunoreactivity represented
endogenous ghrelin or PYY and not non-specific interference,
plasma samples were fractioned by Sephadex G-50 gel per-
meation chromatography [17,18]. The eluted fractions were
assayed for ghrelin and PYY immunoreactivity.
Statistical analysis
A power calculation based on PYY and ghrelin concentration
from an interim analysis suggested a sample size of seven
patients matched to seven controls (at a power of 95%) would
be enough to show significant changes between patients and
control subjects (P < 0.05). The data were analysed using
SPSS 12.0 for windows (SPSS Science, Apache Software
Foundation, Chicago, IL, USA). All data were checked for nor-
mality and presented as mean ± standard error of the mean
(SEM). An independent two-tailed t test was performed to
compare the PYY and ghrelin patterns between patients and
control groups. Correlation analysis was performed using
Pearson correlation coefficient.
Results
Sixteen ICU patients consented to enrolment and were fol-
lowed until discharge. The study enrolment profile is shown in
Figure 1. Four patients who required renal replacement ther-
apy were excluded from the gut hormone final analysis. Four
patients died during the study period and two patients had
less than four blood samples (Table 1). Therefore, the sample
size was reduced to eight eligible patients for ghrelin and PYY
analysis (Table 1).
There was one assay failure for PYY so this reduced the sam-
ple size from eight to seven patients for PYY. We matched
patients and controls for PYY and the number of controls was
reduced accordingly.
Demographics of patients and control volunteers
The comparative mean age and BMI of the patients and con-
trol groups are reported in Table 2. There were 36 healthy vol-
unteers aged 54.3 ± 2.9 years (range 29 to 83 years) with a
BMI of 25.8 ± 0.8 kg/m2 (range19.8 to 40 kg/m2) recruited at
Hammersmith Hospital (Table 2). Table 1 provides data on
methods of feeding, APACHE II and risk of death scores,
length of stay in the ICU and total hospital stay, diagnosis and
reason of admission of patients to the ICU. Length of stay in
the ICU was 12.9 ± 2.2 days (range 2 to 30 days) and total
hospital stay was 40.3 ± 6.6 days (range 9 to 84 days). The
results of the ghrelin and PYY assays from control subjects (lit-
tle day to day variation) were grouped together as a pseudo
normal range of mean ± SEM, with each subject contributing
three data points.
Figure 1
Flow of intensive care patients through the study Flow of intensive care patients through the study. d, day; ITU, intensive 
therapy unit.Critical Care    Vol 10 No 1    Nematy et al.
Page 4 of 9
(page number not for citation purposes)
Table 1
Diagnosis of ICU patients
No. Age (years) Feeding 
method
Target 
energy in 
ICU
APACHE II ROD LOS (ICU) LOS (total) Diagnosis Reason for 
admission to 
ICU
1a 68 Enteral-NG 1,800 27 0.302 12 48 MVR, 
hypotensive 
perioperatively
Haemodynamic, 
respiratory and 
renal instability
2b 57 Enteral-NG 1,800 14 0.106 14 42 Cardiac 
tamponad 
following heart 
surgery
Haemodynamic 
and respiratory 
disruption
3b 72 Oral 2,000 23 0.489 4 45 Chest pain and 
collapse
Haemodynamic 
and respiratory 
disruption
4b 75 Enteral-NG 1,800 25 0.561 4 26 Biliary sepsis Haemodynamic 
instability
5a 77 Oral 1,700 23 0.46 9 17 COPD and 
pneumonia
Haemodynamic 
instability
6b 35 TPN 2,000 16 0.256 16 60 Acute 
pancreatitis
Haemodynamic 
and respiratory 
instability
7c 18 Enteral-NG 1,900 16 0.256 8 10 Congenital 
abnormality in 
lung vessels
Haemodynamic 
and respiratory 
disruption
8b,c 82 Enteral-NG 1,800 20 0.517 25 47 Sigmoid 
vulvulous, 
large bowl 
resection
Haemodynamic 
and respiratory 
disruption
9b 73 TPN 1,700 15 0.126 14 25 Post 
relaparatomy 
following 
pancreatecto
my
Haemodynamic 
and respiratory 
disruption
10 66 Oral 1,800 13 0.227 6 9 Angioplasty-
post insertion 
of stent
Haemodynamic 
instability
11a,c 64 Enteral-NG 1,800 12 0.07 30 81 Post-emergency 
laparotomy
Renal instability
12a 64 Enteral-NG 1,900 22 0.45 10 84 Post-emergency 
laparotomy
Haemodynamic 
and respiratory 
disruption
13b 43 Enteral-NG 2,000 13 0.143 30 76 Global cerebral 
damage 
following 
hypoglycaemia
Hypoglycaemic 
coma
14c 43 Enteral-NG 2,265 12 0.239 13 20 Craniotomy for 
intracerebral 
bleeding
Mental 
deterioration 
due to 
haemorrhage 
in cerebellum
15b 80 Enteral-NG 1,800 35 0.823 10 45 Diabetic coma-
NIDDM
Diabetic come, 
collapsed at 
home
16 40 Oral 1,900 17 0.649 2 10 Sepsis 
(leukaemia)
General 
deterioration 
and confusion
aPatients with renal failure who were dialysis dependent. bPatients were considered for ghrelin and peptide YY statistics. cPatients died during stay 
in hospital. APACHE, Acute Physiology and Chronic Health Evaluation; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; 
LOS, length of stay; MVR, mitral valve prolapse; NIDDM, non-insulin-dependent diabetes mellitus; NG, nasogastric; ROD, risk of death; TPN, total 
parenteral nutrition.Available online http://ccforum.com/content/10/1/R10
Page 5 of 9
(page number not for citation purposes)
Gut hormones
PYY
Fasting PYY levels were significantly higher in the ICU patients
compared to the control group, as can be seen in Figure 2.
Over the period of admission, however, PYY levels signifi-
cantly fell; at days 21 and 28 there was no significant differ-
ence between the ICU group and the healthy controls. There
was no significant difference between the initial plasma level
of PYY in patients and the one prior to discharge due to a large
variation of the level on day one (SEM = 9.6; Table 3). How-
ever, there were significant differences between the plasma
level of PYY on days three and five of admission and that prior
to discharge (34 ± 5.9 and 40.7 ± 7.9 versus 22.3 ± 6.3,
p < 0.05 and p = 0.02, respectively; Table 3).
Renal failure is known to be associated with high levels of
PYY, and it is currently unclear whether this represents the
active PYY3–36 [19]. Of 16 patients, four had renal failure and
significantly higher PYY levels than those patients that did not
have renal failure (day 3 in ICU, 62.2 ± 5.2 versus 34.0 ± 5.9
pmol/l, p < 0.05). We defined renal failure here as dialysis
dependency or chronic renal failure; these four patients
received dialysis in ICU and were removed from subsequent
analysis. A significant difference in PYY levels between
patients and the control group is still clearly apparent, even
with the removal of data for the four renal failure patients (Fig-
ure 2).
Ghrelin
Figure 3 shows that fasting ghrelin levels were significantly
lower in the ICU patients compared with the control group dur-
ing the first three weeks of stay; however, this difference dis-
appeared over the fourth week of stay. There was a significant
difference between initial levels of ghrelin and that prior to dis-
charge (Table 3). As mentioned above, the four patients who
had renal failure were removed from the subsequent analysis.
Among the ICU patients, there was no significant difference
between men and women. There was no significant difference
in PYY and ghrelin concentrations between actual feeding
groups (oral, nasogastric and parenteral nutrition), although
this was an underpowered observation (data not shown).
C-reactive protein
Figure 4 shows the degree of acute phase CRP response dur-
ing ICU stay until day 28. On entering the ICU, patients had
significantly higher CRP levels than the control group (99.6 ±
18.4 versus 2.7 ± 0.5 mg/l, p < 0.005; Figure 4). There was a
statistically significant decrease in CRP levels from the time of
enrolment to the time of discharge (99.6 ± 18.4 versus 25.8
± 10.4 mg/l, p = 0.001; Figure 4), but there was still clear evi-
dence of an acute phase response.
Column chromatography
Gel permeation chromatography demonstrated ghrelin and
PYY immunoreactivity eluted at the same position as synthetic
ghrelin or PYY (data not shown).
Markers of appetite and nutritional status
On entering the ICU, patients had significantly lower albumin
(16.3 ± 1.4 versus 37.4 ± 1.0 g/l, p < 0.005), total protein
(45.6 ± 2.6 versus 70.5 ± 1.0 g/l, p < 0.005), and haemo-
globin (10.0 ± 1.1 g/dl versus 14.1 ± 0.2, p < 0.005) than the
control group. Evaluating appetite using a VAS suggested that
ICU survivors felt less sensation of hunger after discharge
from the ICU (24.7 ± 7.4 versus 40.9 ± 4.8 mm, p = 0.04),
higher nausea (27.3 ± 9.2 versus 5.9 ± 1.4 mm, p = 0.03), and
higher satiety (43.3 ± 13.3 versus 16.5 ± 2.3 mm, p = 0.04)
compared with control volunteers. Mean daily energy intake
after discharge from the ICU was significantly lower in patients
compared to the healthy control subjects (873.4 ± 215.7 ver-
sus 1687.9 ± 40.4 kcal, p = 0.007).
Table 2
Demographic details of intensive care unit patients and control 
subjects
ICU patients Control subjects P value
Subjects (n) 16 36
Age (years) 60 ± 5 54 ± 3 NS
BMI (kg/m2) 28.1 ± 1.7 25.8 ± 0.8 NS
Deceased 4
BMI, body mass index; ICU, intensive care unit; NS, not significant.
Figure 2
Pattern of plasma peptide (PYY; mean ± standard error of the mean)  during intensive care unit (ICU) stay (n = 7 patients) compared with  healthy age and body mass index matched control group (n = 31) Pattern of plasma peptide (PYY; mean ± standard error of the mean) 
during intensive care unit (ICU) stay (n = 7 patients) compared with 
healthy age and body mass index matched control group (n = 31). 
Filled circles, ICU patients; solid line, control group; doted line, error 
bar in control group; * p < 0.05 for patients versus controls. There was 
no significant difference between patients and control subjects on day 
21 and 28. +p < 0.05 for patient day 3 and 5 versus patient day 28.Critical Care    Vol 10 No 1    Nematy et al.
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Markers of appetite and nutritional status changed during stay
(from admission into the ICU until discharge) as follows:
weight decreased (78.4 ± 0.7 versus 68.1 ± 5.2 kg, p = 0.03,
n = 7), MAC decreased (28.8 ± 1.6 versus 26.7 ± .0.7 cm, not
significant), and triceps skinfold thickness decreased (14.8 ±
4.1 versus 13.9 ± 4.6 mm, not significant). Using the VAS,
patients' appetite increased significantly from the time of dis-
charge from ICU to the last week of stay (24.7 ± 7.4 versus
48.3 ± 11.5 mm, p < 0.001). Mean daily energy intake on
week 4 was significantly lower than estimated energy require-
ments (873.4 ± 215.7 versus 1687.0 ± 40.4 kcal, p = 0.007).
Compared to at admission, patients had significantly higher
albumin (23.3 ± 1.5 versus 16.3 ± 1.4 g/l, p < 0.005), total
protein (61.5 ± 3.2 versus 45.6 ± 2.6 g/l, p < 0.005), and hae-
moglobin (11.2 ± 0.4 versus10.0 ± 1.1 g/dl, p < 0.05) on dis-
charge. However, these levels on discharge still did not reach
healthy control subjects' levels (albumin, 23.3 ± 1.5 versus
37.4 ± 1.0 g/l, p < 0.005; total protein, 61.5 ± 3.2 versus 70.5
± 1.0 g/l, p < 0.005; and haemoglobin, 11.2 ± 0.4 versus 14.1
± 0.2 g/dl, p < 0.005).
Correlations
APACHE II scores and day one PYY levels were positively cor-
related (r = 0.5, p = 0.05 (1-tailed)) and negatively correlated
with day one ghrelin (r = -0.3, p > 0.05). Percentage increase
in ghrelin during the stay was negatively correlated with per-
centage change in PYY (r = -0.4, p > 0.05). Decrease in CRP
was positively correlated with decrease in PYY (r = 0.2, p >
0.05) and negatively with decrease in ghrelin (r = -0.35, p >
0.05). A positive association was observed between patients'
food intake at week four and percentage increase in ghrelin
(from week 1 to week 4; r = 0.9, p < 0.05 (1-tailed)) and there
was a negative correlation between food intake and percent-
age decrease in PYY (r = -0.6, p > 0.05). There was a negative
correlation between APACHE II score and appetite on day 14
(r = -0.5, p  = 0.1 (1-tailed)), day 21 (r = -0.7, p  < 0.05
(1-tailed)) and day 28 (r = -0.8, p < 0.1 (1-tailed)).
Discussion
Anthropometric data pointed to a deterioration in the nutri-
tional status of patients during their stay in hospital, with a
decline in body weight, MAC, and albumin and total protein
levels. This is consistent with the finding of Giner and col-
leagues [3], who studied 129 patients admitted to the ICU and
followed them until discharge. Nutrition assessment of our
patients suggested that their nutritional status was poor prior
to admission to the unit, declined further during their stay in the
ICU, and malnutrition continued to be a persistent problem
Figure 3
Pattern of plasma ghrelin (mean ± standard error of the mean) during  intensive care unit (ICU) stay (n = 8 patients) compared with healthy  age and body mass index matched control group (n = 36) Pattern of plasma ghrelin (mean ± standard error of the mean) during 
intensive care unit (ICU) stay (n = 8 patients) compared with healthy 
age and body mass index matched control group (n = 36). Filled cir-
cles, ICU patients; solid line, control group; doted line, error bar in con-
trol group; * p < 0.05. ** p < 0.001 patients versus controls. There was 
no significant difference between patients and control subjects on day 
21 and 28. +p <0.05 for patient day 1 versus patient day 28.
Table 3
Initial and final plasma concentrations of ghrelin and peptide YY of intensive care unit patients
Ghrelin (pmol/l) PYY (pmol/l)
Day 1 Day 28 ± 3 Day 1 Day 28 ± 3
442.4 494.0 22.1 6.4
282.7 516.5 71.6 48.1
43.6 381.4 29.5 19.2
571.2 567.7 22.8 43.6
600.3 743.9 6.1 10.4
126.7 1,136.8ab b
212.7 378.8 61.2 11.4
103.1 232.5 7.0 16.3
297.8 ± 76.3 556.5 ± 98.6c 31.5 ± 9.6 22.2 ± 6.3d
aDischarged home on day 21. bAssay failure. cP < 0.05. dP = 0.17. Values are mean ± standard error of the mean.Available online http://ccforum.com/content/10/1/R10
Page 7 of 9
(page number not for citation purposes)
during remaining hospital stay. Serial measurements of both
mid-upper arm circumference and muscle thickness, using
ultrasound, were made by Reid and colleagues [20] in 50 crit-
ically ill patients. Muscle wasting was identified in 96% of the
patients.
Compared to healthy subjects, our patients exhibited a signif-
icantly lower level of ghrelin and a higher level of PYY during
their stay in the ICU and afterwards. Both levels gradually
returned to normal as they recovered during the further three
weeks of their stay. Several previous studies have also sug-
gested that ghrelin and PYY levels are related to appetite and
nutritional status. Sturm and colleagues [21] found that
plasma ghrelin concentrations were higher in undernourished
than well-nourished groups. English and colleagues [22] and
Rodrigues Ayala and colleagues [23] found plasma ghrelin lev-
els correlated negatively with BMI. Research also indicates
abnormal dynamic levels of PYY and ghrelin in anorexia and
bulimia nervosa [24,25].
We observed lower ghrelin levels and higher PYY levels than
in a healthy control group. PYY decreases and Ghrelin levels
increase over the period of stay in hospital and, as the patients'
medical condition improves, their appetite and food intake
increase. Recent work by our group on patients with cardiac
cachexia caused by severe pulmonary hypertension showed
an exaggerated and early PYY response to a test meal when
compared to control subjects [11].
It is of interest that in all four patients who had renal failure we
found high levels of ghrelin and PYY. Their abnormally high lev-
els of PYY and ghrelin compared to our other patients confirm
previous studies that have suggested that the kidney is an
important site for clearance and/or degradation of PYY and
ghrelin [19,23], although how this observation is reflected in
nutritional status is currently unclear.
We found a negative correlation between ghrelin and PYY. A
49% increase in ghrelin was observed from week one to four
corresponding to a 45% decrease in PYY. Also, food intake
was positively associated with percentage increase in ghrelin
and negatively with decrease in PYY. This is consistent with
other studies of human subjects [7-10]. A human volunteer
study by Batterham and colleagues [10] showed that PYY
infusion reduced plasma levels of ghrelin significantly in both
lean and obese subjects. This suppression of ghrelin by PYY
infusion may add to the anorexigenic effects of PYY. Recent
findings suggest that ghrelin has a role in the regulation of
meal initiation [7].
In our patients, APACHE II scores were correlated positively
with PYY and negatively with ghrelin and appetite during
recovery. There might be an association between severity of ill-
nesses and PYY and ghrelin patterns.
This study had methodological limitations. The study group
represents a typical heterogeneous ICU population with the
associated problems of variability of results. It seems clear,
however, that there are consistent abnormalities in PYY and
ghrelin levels in ICU patients. Furthermore, the use of nasogas-
tric or parenteral nutrition precluded the accurate assessment
of spontaneous food intake and appetite for some patients,
thus reducing sample size for some statistical analyses. Sam-
ple size was also reduced because four patients had renal fail-
ure, which excluded them from the study and four patients
died during the study. Nevertheless, the main aim was to inves-
tigate the pattern of ghrelin and PYY in very sick patients in
hospital and statistically significant results have been estab-
lished in this report. In spite of these limitations and weak-
nesses, observations from this study suggest a possible
relationship between ghrelin and PYY nutritional intake and
nutritional status; consistent with previous studies using PYY
and ghrelin infusion or testing pre- and post-prandial levels in
normal volunteers [7,8,10].
A particular area of interest is the possible effects of the route
of feeding on PYY and ghrelin in ICU patients. In our study,
however, three methods of feeding were used in the sample
patients (parenteral, nasogastric enteral and oral feeding) and
the sample size is too small to draw any conclusions.
Although this is a pilot study on a small number of patients, it
raises the intriguing possibility that appetite regulatory peptide
levels may be changed by critical illness, thus contributing to
continuing nutritional deficits. Further studies are required to
establish the role of ghrelin and PYY in acute illness.
Figure 4
Pattern of plasma C-reactive protein (CRP; mean ± standard error of  the mean) during intensive care unit (ICU) stay (n = 8 patients) com- pared with healthy age and body mass index matched control group (n  = 36) Pattern of plasma C-reactive protein (CRP; mean ± standard error of 
the mean) during intensive care unit (ICU) stay (n = 8 patients) com-
pared with healthy age and body mass index matched control group (n 
= 36). Filled circles, ICU patients; solid line, control group; doted line, 
error bar in control group; *p < 0.05. **p < 0.001 patients versus con-
trols. There was no significant difference between patients and control 
subjects on day 28. +p < 0.05 for patient day 1 versus patient day 28.Critical Care    Vol 10 No 1    Nematy et al.
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This pilot study raises a number of key questions. Why are the
levels of these gut hormones altered in critical illness? What is
the impact of methods of feeding on these hormones? Does
constant feeding have an impact on PYY and ghrelin? What is
the effect of drugs which impairs gastrointestinal function?
What impact does abdominal pathology or reduced splanch-
nic circulation have on gut endocrine mechanism? A final
intriguing question is whether exogenous ghrelin administra-
tion would have any beneficial effect on restoring appetite?
Conclusion
The nutritional status of patients admitted to the ICU decline
over the course of their stay in hospital. Results from our study
show high levels of PYY and low levels of ghrelin compared to
healthy controls. There may be a relationship between the level
of these gut hormones and nutritional intake.
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